CD40 targeting immune checkpoint activators. 350+ patients enrolled; efficacy in neoadjuvant, 1L and post-PD-1/PD-L1 settings, in both PD-1(+) and (-) pts and mult tumor types. Prelim Ph 1b data in 1L panc: robust response/disease control rates and long duration of treatment for APX005M + chemo +/- nivo (2019 AACR). Synergy w/CPI, chemo, etc; favorable safety. 7 Ph 1b and Ph 2 trials in multiple solid tumors incl panc, esophageal and GEJ cancers, NSCLC, metastatic melanoma and sarcoma. Global rights to APX005M. $93M to date (Decheng, 3E, Virtus, SV Tech, Ally Bridge).